Home›Stock Screener›Krebs Biochemicals & Industries›Financial Statements

Krebs Biochemicals & Industries Complete Financial Statements

11 Years of Data
2025 - 2015

In FYNone, Krebs Biochemicals & Industries (KREBSBIO) reported revenue ₹23 Cr, net profit ₹-23 Cr and EPS ₹-10.60, with a net profit margin of -61.4%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review KREBSBIO P/E comparison to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -61.36% 2025 data
EBITDA Margin -31.82% 2025 data
Operating Margin -35.00% 2025 data
Return on Assets -15.98% 2025 data

Balance Sheet Ratios

Current Ratio 0.05 2025 data
Equity Ratio -86.39% 2025 data
Asset Turnover 0.26 2025 data

KREBSBIO Revenue, Net Profit & EBITDA — Year-on-Year Growth

KREBSBIO YoY (March 2025 vs Period) — revenue -47.7%, net profit +14.8%, EBITDA +28.6%, expenses -43.1%. For live price, earnings ratios and company overview, see KREBSBIO stock price BSE.

Revenue Growth
-47.7%
Year-over-Year
Net Profit Growth
+14.8%
Year-over-Year
EBITDA Growth
+28.6%
Year-over-Year
Expense Growth
-43.1%
Year-over-Year
Assets Growth
-5.1%
Year-over-Year
Equity Growth
-22.7%
Year-over-Year
Operating Cash Flow Growth
-500.0%
Year-over-Year
Investing Cash Flow Growth
+37.5%
Year-over-Year
Financing Cash Flow Growth
+116.7%
Year-over-Year

KREBSBIO Income Statement — Revenue, EBITDA & Net Profit

Krebs Biochemicals & Industries revenue ₹23 Cr, EBITDA ₹-10 Cr, net profit ₹-23 Cr, EPS ₹-10.60 (None) — net profit margin -61.4%. Explore Krebs Biochemicals & Industrie intrinsic price to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 23 44 51 53 61 54 34 48 34 3 2 0
Expenses 33 58 59 68 94 71 52 58 41 11 14 5
EBITDA -10 -14 -8 -15 -33 -17 -18 -10 -7 -8 -11 -5
Operating Profit Margin % -47.00% -35.00% -17.00% -30.00% -57.00% -33.00% -56.00% -21.00% -22.00% -246.00% -962.00% 0.00%
Depreciation 6 7 7 7 6 5 5 4 4 4 5 2
Interest 7 6 5 3 5 6 6 6 5 4 1 4
Profit Before Tax -23 -27 -20 -25 -45 -28 -29 -20 -18 -16 -16 -8
Tax 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit -23 -27 -20 -25 -45 -28 -29 -20 -18 -16 -16 -8
Earnings Per Share (₹) -10.60 -12.49 -9.15 -11.30 -20.81 -14.37 -17.90 -12.83 -12.97 -11.68 -12.49 -8.24

KREBSBIO Balance Sheet — Assets, Liabilities & Shareholders' Equity

KREBSBIO total assets ₹169 Cr, total equity ₹-146 Cr, total liabilities ₹ Cr (2025).

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 169 178 175 190 159 134 142 126 122 116 108
Current Assets 10 17 16 36 21 19 31 17 13 9 15
Fixed Assets 146 150 147 139 118 105 101 101 102 93 58
Capital Work in Progress 3 2 4 8 12 4 4 4 4 11 0
Investments 0 0 0 0 0 0 0 0 0 0 0
Other Assets 20 26 24 43 29 24 38 21 16 13 50
LIABILITIES
Total Liabilities
Current Liabilities 212 236 225 187 154 116 102 101 89 74 61
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity -146 -119 -100 -75 -43 -25 -14 -18 2 13 18
Share Capital 22 22 22 22 20 18 17 14 14 13 10
Reserves & Surplus -168 -141 -121 -97 -67 -43 -31 -32 -12 -4 -14

KREBSBIO Cash Flow Statement — Operating, Investing & Financing

Krebs Biochemicals & Industries operating cash flow ₹-8 Cr, investing ₹-5 Cr, financing ₹13 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -8 2 -25 -17 -15 -36 4 -6 -11 -15 -45
Investing Activities -5 -8 -13 -23 -23 -10 -4 -3 -5 -4 -3
Financing Activities 13 6 37 40 38 29 17 9 16 13 54
Net Cash Flow 0 0 0 -1 1 -17 17 0 0 -6 6